黑石集团与德州太平洋集团将收购豪洛捷，每股收购价最高 79 美元。 ...

Core Viewpoint - Hologic is set to be acquired by Blackstone and TPG for up to $79 per share, indicating a significant valuation for the company [1] Group 1 - The acquisition price of up to $79 per share reflects a premium over Hologic's current market valuation [1] - Blackstone and TPG are prominent private equity firms, suggesting a strategic investment in the healthcare sector [1] - This acquisition could lead to potential growth opportunities for Hologic under the management of experienced private equity investors [1]

Core Insights - U.S. stock markets are experiencing a midday rally driven by easing concerns over regional bank stability, de-escalation in U.S.-China trade tensions, and strong performances from tech companies [1][9] Major Market Indexes Performance - The S&P 500 Index (SPX) has increased by approximately 0.7% to 1.0%, nearing its all-time high [2] - The Nasdaq Composite Index (IXIC) is leading with gains between 0.8% and 1.4%, fueled by optimism in AI sectors and strong tech earnings expectations [2] - The Dow Jones Industrial Average (DJIA) has risen around 0.5% to 0.8%, adding over 200 points, indicating renewed investor confidence [2] - The Cboe Volatility Index (VIX) has slightly dipped but remains above 20, indicating some caution among institutional investors [2] Upcoming Market Events - The week of October 20-24, 2025, features a busy financial calendar with significant corporate earnings reports expected from major companies like Coca-Cola, Tesla, and Procter & Gamble [3] - Other notable companies reporting include Netflix, IBM, Intel, General Motors, Ford, Lockheed Martin, and RTX [3] - Regional banks such as Zions Bancorp and Western Alliance Bancorp are also set to report, with a focus on loan quality [3] Economic Indicators - The ongoing U.S. government shutdown is affecting the data landscape, but the September Consumer Price Index (CPI) report is anticipated on October 24, providing insights into inflation trends [4] - Key economic indicators to monitor include S&P Global flash PMIs and existing home sales [4] Major Stock News and Developments - Apple (AAPL) shares have surged over 4%, reaching a new all-time high due to strong demand for the iPhone 17 series [5] - Amazon (AMZN) shares have recovered after an initial dip, despite an AWS outage affecting several online services [6] - Smaller and mid-sized bank stocks are recovering after previous losses, while Moderna (MRNA) shares are up approximately 7% following positive vaccine data [7] - Beyond Meat (BYND) has soared over 68% due to a short squeeze, and Cleveland-Cliffs (CLF) has increased by over 24% after strong earnings [7] - Kering (KER) rose 3.6% after agreeing to sell its Kering Beaute division to L'Oreal for €4 billion [7]

Shares of Hologic Inc (NASDAQ:HOLX) are up 2.4% to trade at $71.51 at last glance, earlier tapping $73.09 their highest level since early January. Driving the upbeat price action is a Bloomberg report that Blackstone (BX) and TPG (TPG) are looking to buy the medtech giant for $17 billion. HOLX is still stuck below its year-to-date breakeven level, but has now broken above recent overhead pressure at $70. Today's outperformance has the shares eyeing a fifth-straight win, a bounce that originated at their 100 ...

Core Insights - Hologic (HOLX) is scheduled to release its fourth-quarter fiscal 2025 results on November 3, with earnings per share (EPS) estimated to increase by 8.9% year over year to $1.10 and revenues projected to rise by 4.7% to $1.03 billion [1][5]. Financial Performance - The Zacks Consensus Estimate for fiscal fourth-quarter EPS has remained stable over the past 60 days, indicating no revisions [1][2]. - Hologic's earnings performance over the trailing four quarters has been mixed, with three beats and one miss, averaging a surprise of 0.96% [2][3]. Segment Analysis - The Diagnostics unit is expected to face macroeconomic pressures, limiting growth potential, while the Breast Health and GYN Surgical divisions are showing modest gains [5][20]. - The Molecular Diagnostics unit is anticipated to drive growth, particularly in the U.S. vaginitis market, and the oncology business may benefit from the Breast Cancer Index test [6][7]. - The Breast Health division is likely to return to growth, supported by new leadership and improved sales strategies, with a projected 0.1% year-over-year revenue increase [8]. - The GYN Surgical division is expected to deliver strong revenue performance, with an 11.9% year-over-year increase, driven by international markets and new product reimbursements [9]. - The Skeletal Health division is projected to see significant growth of 144.8% year-over-year, rebounding from previous operational challenges [10]. Market Position and Valuation - Year-to-date, Hologic shares have declined by 3.2%, underperforming compared to the industry average decline of 8.1% [11]. - The stock is currently trading at a forward Price/Sales (P/S) ratio of 3.64, above its median of 3.47 and the sector's 2.30 [15]. Strategic Considerations - Hologic is focusing on innovation and market access, with new product launches and a strong emphasis on operational efficiency [17][18]. - The company faces ongoing macroeconomic challenges, including tariffs that may impact gross margins and revenue expectations, particularly in China [19][20].

Core Viewpoint - Hologic's stock performance has been mixed, with a recent increase but a decline over the past month, and upcoming earnings are anticipated to show growth in earnings per share and revenue [1][2][3]. Company Performance - Hologic closed at $68.50, reflecting a +2.24% change from the previous day, outperforming the S&P 500, which fell by 0.63% [1]. - Over the last month, Hologic's shares decreased by 1.76%, while the Medical sector gained 3.09% and the S&P 500 increased by 0.92% [1]. Upcoming Earnings - The earnings report is expected on November 3, 2025, with projected earnings of $1.1 per share, indicating a year-over-year growth of 8.91% [2]. - The Zacks Consensus Estimate for revenue is $1.03 billion, representing a 4.67% increase from the previous year [2]. Full Year Estimates - For the full year, analysts expect earnings of $4.24 per share and revenue of $4.08 billion, reflecting changes of +3.92% and 0% respectively from last year [3]. - Recent changes in analyst estimates are crucial as they often indicate shifts in near-term business trends [3]. Analyst Ratings - Hologic currently holds a Zacks Rank of 4 (Sell), with a recent 0.11% decrease in the Zacks Consensus EPS estimate over the last 30 days [5]. - The Zacks Rank system has a strong track record, with stocks rated 1 producing an average annual return of +25% since 1988 [5]. Valuation Metrics - Hologic has a Forward P/E ratio of 14.96, which is lower than the industry average of 23.97 [6]. - The company has a PEG ratio of 2.3, compared to the industry average PEG ratio of 2.54 [6]. Industry Context - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 89, placing it in the top 37% of over 250 industries [7]. - Strong industry rankings correlate with stock performance, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7].

Hologic (NASDAQ:HOLX) rose 2% in premarket trading after a report about financing for a potential takeover by Blackstone (BX) and TPG Inc. (TPG). Direct lenders are preparing a $9 billion debt financing package as they attempt to compete with banks to ...

Company Overview - Hologic, Inc. (HOLX) is a Massachusetts-based medical technology company with a market cap of $14.7 billion, specializing in women's health through diagnostic products, medical imaging systems, and surgical devices [1] Financial Performance - For fiscal Q4 2025, analysts project an adjusted EPS of $1.10, representing an 8.9% increase from $1.01 in the same quarter last year [2] - For fiscal 2025, the expected adjusted EPS is $4.24, up 3.9% year-over-year from $4.08 in fiscal 2024, with a further increase to $4.48 expected in fiscal 2026, reflecting a 5.7% year-over-year growth [3] Stock Performance - HOLX stock has declined 18% over the past 52 weeks, underperforming the S&P 500 Index, which gained 14.7%, and the Health Care Select Sector SPDR Fund, which declined by 6.7% during the same period [4] Recent Developments - On October 2, Hologic shares rose 1.3% following FDA clearance for its Panther Fusion® Gastrointestinal Bacterial and Expanded Bacterial Assays, which are designed to quickly detect common bacterial pathogens causing infectious gastroenteritis [5] Analyst Ratings - Analysts maintain a "Moderate Buy" rating for HOLX, with 20 analysts covering the stock: eight recommend "Strong Buy," two suggest "Moderate Buy," and ten advise "Hold." The mean price target of $75.25 indicates a potential upside of 12.3% from current price levels [6]

Core Viewpoint - Hologic (HOLX) has been trending in stock searches, with a recent performance of +2.7% over the past month, outperforming the S&P 500's +1.1% and the Zacks Medical - Instruments industry's -6.2% [1] Earnings Estimates - For the current quarter, Hologic is expected to report earnings of $1.10 per share, reflecting an increase of +8.9% year-over-year, although the Zacks Consensus Estimate has decreased by -0.3% in the last 30 days [4] - The consensus earnings estimate for the current fiscal year is $4.24, indicating a +3.9% change from the previous year, with a slight decrease of -0.1% over the last month [4] - For the next fiscal year, the consensus estimate is $4.48, showing a +5.6% increase from the prior year, with no change in the estimate over the past month [5] Revenue Growth - Hologic's consensus sales estimate for the current quarter is $1.03 billion, representing a year-over-year increase of +4.7% [10] - The sales estimates for the current and next fiscal years are $4.08 billion and $4.26 billion, indicating changes of +1.4% and +4.3%, respectively [10] Recent Performance and Surprise History - In the last reported quarter, Hologic achieved revenues of $1.02 billion, a +1.2% increase year-over-year, and an EPS of $1.08, compared to $1.06 a year ago [11] - The company surpassed consensus EPS estimates three times and revenue estimates three times over the last four quarters [12] Valuation - Hologic is graded B in the Zacks Value Style Score, suggesting it is trading at a discount compared to its peers [16]

Core Insights - Hologic (HOLX) is experiencing strong momentum in its GYN Surgical portfolio, reflecting a growing global focus on women's health [1] - The company has expanded its market reach for minimally invasive surgical products through investments in commercial and market access capabilities outside the U.S. [1] - NovaSure, a product for treating abnormal uterine bleeding, has shown double-digit growth internationally despite domestic challenges [1] Market Overview - The U.S. uterine fibroids treatment devices market is projected to grow from $2.77 billion in 2024 at a CAGR of 9.3% through 2030 [2] - Women typically wait an average of 3.5 years before seeking treatment for fibroids, with hysterectomy being the most common option [2] - Increased awareness of minimally invasive treatment options presents growth opportunities for Hologic [2] Product Development and Acquisitions - Growth in the GYN Surgical segment has been driven by products like MyoSure and Fluent, along with strategic acquisitions such as Acessa Health in 2020 [3] - The recent acquisition of Gynesonics enhances Hologic's capabilities in treating mid-sized fibroids [3] Financial Performance and Projections - Hologic anticipates the fourth quarter of fiscal 2025 to be the strongest for revenue growth in the GYN Surgical segment, forecasting an 11.9% year-over-year growth [4] - Hologic shares have decreased by 19.7% over the past 12 months, compared to a 15.5% decline in the industry [7] Competitive Landscape - Major competitors in the GYN Surgical segment include Medtronic and Johnson & Johnson, both of which are advancing their own surgical solutions [5][6] - Medtronic has initiated a clinical study for its Hugo robotic-assisted surgery system, while Johnson & Johnson has reached a milestone with its TECNIS ODYSSEY lenses [5][6] Valuation Metrics - Hologic is currently trading at a forward 12-month price-to-sales (P/S) ratio of 3.42X, which is lower than the industry average of 3.98X [9]